L’anticorps Souris Monoclonal anti-IL2RA (Daclizumab Biosimilar) a été validé pour FACS et in vivo. Il convient pour détecter IL2RA (Daclizumab Biosimilar) dans des échantillons de Humain.
N° du produit ABIN7795104
Aperçu rapide pour Recombinant IL2RA (Daclizumab Biosimilar) anticorps (ABIN7795104)
Antigène
IL2RA (Daclizumab Biosimilar)
Type d'anticorp
Recombinant Antibody
Reactivité
Humain
Hôte
Souris
Clonalité
Monoclonal
Conjugué
Cet anticorp IL2RA (Daclizumab Biosimilar) est non-conjugé
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Classe de qualité
Research Grade
Expression System
Mammalian cells
Fonction
Daclizumab Biosimilar, CD25 Monoclonal Antibody
Attributs du produit
Daclizumab Biosimilar uses the same protein sequences as the therapeutic antibody daclizumab. Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90 % ) and murine (10 %) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.